Groups
Company Size (Fulltime employees)
Looking for
Functionality
Headquartner in China
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Medtech Category
Medtech Development Stage
Index
Countries
Reset

Mr. Jake Townsend United States

Celumigen Pharmaceuticals is a California- headquartered seed stage specialty pharmaceutical company in dermatology focused on developing the first FDA-approved topical prescription immunotherapeutic drug for Cutaneous viral warts; a widespread global disease affecting greater than 500MM people in China, and 78% of the world's population. The global markets have seen no approved prescription therapies for HPV, Common warts and no therapies that eradicate this disease on the market or in the pipeline-- we plan to capture and grow this lucrative market. Our therapeutic is a likely 505 (b) 2 FDA designated drug. Our leadership, development and clinical team is a group of world class leaders with deep industry knowledge and unparalleled domain expertise. We have raised a seed round led by industry- leading investors which funded a Proof of Concept study with very positive confirmatory results and data to support our Phases I and Phase II. We are now seeking strategic partnership with a company seeking to support drug development to enhance existing dermatology drug asset portfolios or fund our program through venture capital / partnership.
Website:
celumigen.com
Company Size (Fulltime employees)
1-10
Looking for
Please specify your partnering goal
Strategic investment/ partnership
Headquartner in China
No
Plan in China
The Chinese market for our therapeutics pipeline is among the largest and most promising in the world. Greater than 500 Million Chinese people suffer from Cutaneous viral warts, with no approved therapies and none that eradicate warts. We plan on capturing this market and growing in the Chinese pharmaceutical market, and from there, growing into the rest of the world. China represents a vital vantage point to penetrate markets that may not be available to US based companies. Our goal to benefit with a strategic partner based in China would be to develop our existing drug target, and widening our asset portfolio in topical drugs in dermatology in order to create a Chinese based company with an exceptional specialty pharmaceutical dermatology asset portfolio.
Biotech/Pharma Category
Celumigen Pharmaceuticals
CEO 

Jacky Wang United States

华诺临床立足于海外,为全球客户提供医药产品在北美进行 FDA 临床报批、临床试验运营、临床数据分析与管理等一系列服务。专业的团队,丰富的经验以及客户至上的合作理念会助您拓展在海外的临床开发业务。客户的满意与成功是我们追求的终极目标。
Website:
https://www.huanuoclinical.com/
Looking for
Headquartner in China
No
Service Description
研发工具或服务 Research tools and services: Clinical CRO, Regulatory Consulting
Nova Clinical Solutions, Inc.
President 

jun xia United States

Able Cerebral is currently apply phase III clinical study with FDA for its controlled release of brain energy product. The product has shown remarkable therapeutic effectiveness for mid-stage and early stage Alzheimer's disease.

Able Cerebral is also developing a game changing, non-invasive medical device that will consolidate and recovery of brain memory for mid-stage and late stage Alzheimer's disease.

Website:
www.ablecerebral.com
Year of foundation
2012
Looking for
Funding Status
looking for investors or partners for advance our product and programs. Able Cerebral is ready to convert to Delaware C-Corp
Headquartner in China
No
Plan in China
We were planning to engage some sci-tech park in China before the pandemic.
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Medtech Category
Medtech Development Stage
Slides Deck
(pptx, 308.49KB)
able cerebral
Co-Founder / President 
Functionality
Management

John Xu United States

Bi-Specific antibody drug discovery
Website:
www.Abpro.com
Year of foundation
2004
Looking for
Please specify your partnering goal
Pre IPO fund raising
Headquartner in China
No
Plan in China
Set up subsidiary in China next year
Biotech/Pharma Category
Investment Focus
Looking for investors
Abpro
SVP 
Functionality
Business Development

Wenjie Xu United States

As China Focus conference organizer, MyBioGate is a premier cross-border healthcare consulting firm serving Biotech and Medtech clients, and the Chinese Pharma companies and investors. We offer marketing, strategy and execution support to help healthcare innovation to grow by taking advantage of China’s huge market potential. We help innovative companies with China-Landing services, and help them find reliable Chinese investors and partners. MyBioGate is committed to linking healthcare innovations in China and overseas. We share global healthcare innovation, entrepreneurship, investment trends, KOL opinions, important events and conferences, in-depth research and analysis, allowing Chinese medical and health companies and investors to gain insight into trends and seize investment opportunities. Our China Focus forums, Global Healthcare Innovation Competitions, and road shows to China provide innovative companies who intend to enter China market with platforms for exposure to potential investors and partners.

Website:
https://en.mybiogate.com/
Mybiogate Inc.
Investment Manager 

Joanne Yang United States

Syneos Health is the only company in the biopharmaceutical services industry purpose-built to create greater success for our customers. At Syneos Health, clinical and commercial live under the same roof and constantly share real world knowledge and insights that lead to getting the job done better, smarter and faster.

Syneos Health has around 24,000 + employees globally. We are headquartered in US, North Carolina and has more offices in more than 60 countries worldwide. In China, we have offices in Shanghai, Beijing and Dalian.

We call this new way of collaborative working the Biopharmaceutical Acceleration Model or BAM.
Website:
https://www.syneoshealth.com/our-company
Looking for
Headquartner in China
No
Syneos Health
Director, Business Development 
Functionality
Business Development

Simon Yi United States

PhysioCue is digital health and therapy device development company, located in the heart of Silicon Valley, California. PhysioCue has developed the thermal neurostimulation technology for a non-invasive hypertension therapy device and a migraine and headache therapy device and migraine and headache pain monitoring mobile app. Using our device once daily for 5-minute treatments gradually elongated the reduced blood pressure. PhysioCue's therapy devices are efficient, safe, easy to use, and has none of the side effects associated with drugs. We have manufactured our devices and delivered devices to our potential partners and users. We've received positive feedback from many people who have tried and liked our devices. PhysioCue devices can help people and save lives.
Website:
https://physiocue.com
Company Size (Fulltime employees)
1-10
Year of foundation
2013
Looking for
Funding Status
PhysioCue is seeking to raise $7M for a syndicate in our Series A round of financing.
Headquartner in China
No
Plan in China
Set up a JV in China and looking for a distribution partner.
Medtech Category
PhysioCue
LinkedIn logo President 
Functionality
Management

Xudong Yuan United States

Acon Pharmaceuticals Inc. (Acon Pharma) is a specialty pharmaceutical company and focuses on BLA, ANDA, and 505(b)(2) NDA drug product development with its captive drug delivery system technology platforms. Acon Pharma provides service to its partners and customers to accelerate their IND and NDA product development by out-licencing its captive drug delivery platforms, pre-formulation, formulation, process development, and manufacturing of different types of dosage forms and drug delivery products. Our expertise covers drug development and delivery of poorly soluble small molecule drugs, siRNA, oligonucleotides, peptides, protein, and plasmid DNA. Our formulation technology platforms include nanoparticles, microspheres / microparticles, nanocrystals, liposome, implant, long-acting injectable, oral fast dissolving film (ODF), transdermal patches, resinate / polistirex suspension, nasal spray, topical cream, gel, ointment, nanoemulsion, microemulsion, self-emulsifying system, tablets, capsules, inhalers, controlled release, modified release, and delayed release.
Website:
www.aconpharma.com
Year of foundation
2019
Looking for
Please specify your partnering goal
Looking for investors and strategic partners
Funding Status
Seed round
Now raising (In USD)
5 million USD
Headquartner in China
No
Plan in China
We are establishing a China headquarter company in Shanghai.
Biotech/Pharma Category
Assets Information 1: Name|Description|Indications|Stage|IP countries
AP1500|siRNA liposome inhalation|pulmonary fibrosis|Pre-IND|US, China
Assets Information 2
AP2602|Long acting microsphere injection|schizophrenia|Pre-IND|US, China
Assets Information 3
AP6111|Self-emulsifying Nanoemulsion|osteoporosis|Pre-IND|US, China
Acon Pharma
CEO 
Functionality
Management

Kristina Zakurdaeva United States

Incuron is a private clinical-stage company that develops a novel class of synthetic small molecules, Curaxins, with a unique multi-targeted mechanism of antitumor activity. These chromatin damaging agents interfere with histone/DNA binding causing decondensation of chromatin in tumor cells, functional inactivation of histone chaperone FACT, and simultaneous effect on a set of universal previously undruggable targets, leading to inhibition of pro-cancer transcriptional factors, MYC, NF-kB, HIF1a, and HSF-1, and activation of the tumor suppressor p53, as well as induction of type I interferon response.
Key advantages of curaxins based on current preclinical and early clinical data include:
- novel mechanism of action that would bring the additional treatment option for advanced and relapsed tumors, as well as potential to overcome resistance to previous treatments;
- favorable pharmacology and manageable safety profiles;
- low potential for serious drug-drug interactions providing opportunities for combinatorial therapeutic regimens;
- broad activity in different tumor types that may open wider market opportunities;
- focused phase 2 clinical study program can establish faster clinical proof of concept and build toward accelerated regulatory approval.
Incuron owns a worldwide patent portfolio, including the composition of matter and therapeutic uses of the compounds.
Website:
incuron.com
Looking for
Headquartner in China
No
Plan in China
Incuron is currently seeking investors and partners for co-development to execute Phase 2 clinical program or out-licensing opportunities.
Incuron, Inc.
CEO 
Functionality
Management

Bo Zhang United States

KLUS Pharma
VP